Nilotinib 300 mg BID in Newly Diagnosed CP-CML Patients to Verify Disappearance of CD34+/Lin-Ph+ Cells

Clinical trial NCT01856283 · COMPLETED

Trial details

NCT number: NCT01856283
Sponsor: Niguarda Hospital
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Leukemia, Myeloid, Chronic-Phase

Start date: 2013-03-01
Primary completion: 2020-07-01
Enrollment: 87

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.